Avis Budget Group, Inc. (CAR)
Disount To Net Cash For A Promising CAR-T Company
Galapagos NV announced a strategic split with Gilead Sciences, creating 'New Galapagos' and 'SpinCo', aiming to unlock shareholder value and reduce staffing by 40%. 'New Galapagos' will focus on cell therapies and small molecules, while 'SpinCo' will target oncology, immunology, and virology with €2.45 billion in capital. Despite an 18% share decline post-announcement, the split offers deep value and potential catalysts, though risks include governance concerns, competitive CAR-T space, and executional challenges.
Canadian Apartments: You Have To Step Up To Buy Here
CAPREIT reported strong Q4-2024 results. Notable items included a 3% distribution hike and a very substantial buyback. We go over the results and tell you why we are upgrading to a strong buy.
Avis Budget Stock Price Decreases 7% Since Reporting Loss in Q4
CAR's top line in the fourth quarter of 2024 takes a hit as revenues in the Americas decline.
Avis Budget Group, Inc. (CAR) Q4 2024 Earnings Call Transcript
Avis Budget Group, Inc. (NASDAQ:CAR ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants David Calabria - SVP, Corporate Finance and Treasurer Joseph Ferraro - President and CEO Izilda Martins - EVP and CFO Brian Choi - Executive VP and Chief Transformation Officer Conference Call Participants John Babcock - Bank of America Christopher Stathoulopoulos - Susquehanna Financial Harold Antor - Jefferies Jash Patwa - J.P. Morgan Chase Dan Levy - Barclays Bank Chris Woronka - Deutsche Bank Operator Greetings, and welcome to the Avis Budget Group's Fourth Quarter and Full Year 2024 Conference Call.
Avis Budget (CAR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Avis Budget Group (CAR) Reports Q4 Loss, Misses Revenue Estimates
Avis Budget Group (CAR) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to earnings of $7.10 per share a year ago.
5 Broker-Favorite Stocks to Keep an Eye on Amid Current Volatility
Investors should keep a tab on stocks like General Motors, Dana, Valero Energy, National Vision and Avis Budget for high returns.
Avis Budget Group (CAR) Expected to Beat Earnings Estimates: Should You Buy?
Avis Budget (CAR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Should Hold Avis Budget Stock in Your Portfolio Now
CAR benefits from strong demand, fleet management and technology investments, which boost profitability. However, lack of dividends and low liquidity pose risks.
Hemogenyx Pharmaceuticals partners with Kure.ai for ultrafast CAR-T manufacturing
Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF). the UK-listed biopharmaceutical company focused on treatments for blood cancers, has entered a collaboration with Kure.ai to develop an ultrafast manufacturing process for its CAR-T cell therapies.
Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Over the weekend, Bristol Myers Squibb & Co BMY shared preliminary data from a Phase 1 study of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process for severe, refractory autoimmune diseases.
Avis Budget Stock Appreciates 12% Despite Earnings Miss in Q3
CAR's third-quarter 2024 top line witnesses a decline due to a fall in revenues from the Americas.
